Sherlock Biosciences
Sherlock Biosciences is a biotechnology company based in Cambridge, Massachusetts developing diagnostic tests using CRISPR-Cas13. The company was founded in 2019[1] by Feng Zhang, Jim Collins, Omar Abudayyeh, and Jonathan Gootenberg of the Broad Institute.[2]
Cas13 was discovered by Zheng and Eugene Koonin using computational biology methods, and then further characterized by Jennifer Doudna's team at the University of California, Berkeley. In 2020, both Sherlock Biosciences and Mammoth Biosciences from Doudna's lab at UC Berkeley used their similar CRISPR technologies to develop tests for COVID-19.[3][4]
In 2021, Sherlock Biosciences and The Forsyth Institute entered into a strategic partnership with its focus being on the research and development of products related to the “detection of human biomarkers in oral cavity and other oral health applications."[citation needed]
See also
[edit]External links
[edit]References
[edit]- ^ "Sherlock Biosciences". Craft.co. Retrieved 2021-05-27.
- ^ Kincaid, Ellie. "With Launch Of New CRISPR Company, Competition Extends To Diagnostics". Forbes. Retrieved 2022-04-14.
- ^ "SHERLOCK-based one-step test provides rapid and sensitive Covid-19 detection". MIT News | Massachusetts Institute of Technology. 5 May 2020. Retrieved 2022-04-14.
- ^ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 427–433. ISBN 978-1-9821-1585-2.
 | This corporation or company article is a stub. You can help Wikipedia by expanding it. |